Consistent with these studies, we found that FOXF1 stabilizes blood vessels inside the NSCLC tumors, which can be utilized to enhance delivery of chemotherapeutic agents or immune checkpoint inhibitors in NSCLC therapy. Here, FOXF1 is linked to non-small cell lung carcinoma.